Boston Scientific’s stronger margins contrast with softer product expectations, placing portfolio execution, restructuring, and medical-device innovation at the center of its outlook.
Procter & Gamble faces margin pressure despite stable revenue as productivity programs, cost inflation, brand strength, and cautious guidance shape its outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results